When Regulatory Precedent Is Not Enough

The most experienced regulatory teams know how to read precedent. They know which predicates were accepted, how FDA has historically evaluated similar technologies, and which arguments have worked before.

That expertise matters. In surgical robotics, aesthetic and reconstructive devices, and other technologies whose performance depends on workflow, user technique, software, or clinical context, precedent is only a starting point.

These products may not fit cleanly into what came before. The comparator may be imperfect. The endpoint may not capture what matters in use. The failure modes may differ from those of prior devices. FDA’s questions may concern the product’s actual clinical setting rather than what was accepted previously.

The resulting problems are predictable: questions the team did not anticipate, requests for data that do not follow precedent, or late recognition that the evidence and clinical use were not aligned.

Companies navigate these issues by evaluating the specific device, claims, users, risks, and clinical setting rather than relying only on prior submissions.

For new technologies, precedent informs the analysis. It does not complete it.